Bioventures Ltd Novartis Net Worth

The estimated Net Worth of Bioventures Ltd Novartis is at least $263 Тысяча dollars as of 25 March 2014. Bioventures Novartis owns over 182,590 units of Akebia Therapeutics stock worth over $262,930 and over the last 11 years Bioventures sold AKBA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Bioventures Novartis AKBA stock SEC Form 4 insiders trading

Bioventures has made over 1 trades of the Akebia Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently Bioventures bought 182,590 units of AKBA stock worth $3,104,030 on 25 March 2014.

The largest trade Bioventures's ever made was buying 182,590 units of Akebia Therapeutics stock on 25 March 2014 worth over $3,104,030. On average, Bioventures trades about 182,590 units every 0 days since 2014. As of 25 March 2014 Bioventures still owns at least 182,590 units of Akebia Therapeutics stock.

You can see the complete history of Bioventures Novartis stock trades at the bottom of the page.

What's Bioventures Novartis's mailing address?

Bioventures's mailing address filed with the SEC is 131 FRONT STREET, , HAMILTON, D0, HM 12.

Insiders trading at Akebia Therapeutics

Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter и Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.

What does Akebia Therapeutics do?

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

Complete history of Bioventures Novartis stock trades at Akebia Therapeutics

Akebia Therapeutics executives and stock owners

Akebia Therapeutics executives and other stock owners filed with the SEC include:

• John Butler,
  President, Chief Executive Officer, Director
• Michel Dahan,
  Chief Operating Officer, Senior Vice President
• Nicole Hadas,
  Senior Vice President, Chief Legal Officer, Corporate Secretary
• Dell Faulkingham,
  Senior Vice President, Chief Commercial Officer
• John P. Butler MBA,
  CEO, Pres & Director
• Dr. Steven Keith Burke,
  Sr. VP of R&D and Chief Medical Officer
• Dell Faulkingham,
  Sr. VP & Chief Commercial Officer
• Michel Dahan,
  Sr. VP & COO
• Jason A. Amello,
  Exec. Officer
• Adrian Adams,
  Independent Chairman of the Board
• Michael Rogers,
  Independent Director
• Maxine Gowen,
  Independent Director
• Michael Heffernan,
  Independent Director
• Cynthia Smith,
  Independent Director
• Mark Enyedy,
  Independent Director
• Steven Gilman,
  Independent Director
• Kristen Sheppard,
  Vice President, Investor Relations
• Myles Wolf,
  Independent Director
• Steven Burke,
  Senior Vice President, Chief Medical Officer
• David Spellman,
  Chief Financial Officer, Senior Vice President, Treasurer
• Douglas Jermasek M.B.A.,
  VP of Marketing & Strategy
• Mercedes Carrasco,
  Director of Corp. Communications
• Nicole R. Hadas,
  Sr. VP, Chief Legal Officer & Sec.
• Violetta Cotreau,
  Sr. VP, Chief Accounting Officer & Principal Accounting Officer
• Scott A Canute,
  
• Duane Nash,
  Director
• Ronald C Jr Renaud,
  Director
• Muneer A Satter,
  Director
• Michael D. Clayman,
  Director
• Bradley Maroni,
  SVP & Chief Medical Officer
• Anupam Dalal,
  Director
• Michael S Wyzga,
  Director
• Rita Jain,
  SVP, Chief Medical Officer
• Karen L Tubridy,
  SVP, Chief Development Officer
• Leanne M Zumwalt,
  
• Ron Frieson,
  
• Jodie Pope Morrison,
  
• Robert Shalwitz,
  Chief Medical Officer
• Bioventures Ltd Novartis,
  10% owner
• Holdings A/S Novo,
  10% owner
• Violetta Cotreau,
  SVP, Chief Accounting Officer
• Jason Amello,
  SVP, CFO & Treasurer
• Ellen Snow,
  SVP, CFO and Treasurer
• Nicholas Grund,
  Chief Commercial Officer
• Richard C Malabre,
  Chief Accounting Officer
• Erik Ostrowski,
  SVP, CFO, CBO & Treasurer